MY208876A - Trispecific binding proteins, methods, and uses thereof - Google Patents
Trispecific binding proteins, methods, and uses thereofInfo
- Publication number
- MY208876A MY208876A MYPI2021005932A MYPI2021005932A MY208876A MY 208876 A MY208876 A MY 208876A MY PI2021005932 A MYPI2021005932 A MY PI2021005932A MY PI2021005932 A MYPI2021005932 A MY PI2021005932A MY 208876 A MY208876 A MY 208876A
- Authority
- MY
- Malaysia
- Prior art keywords
- binding
- binding proteins
- polypeptide
- binds
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
Abstract
Provided herein are trispecific and/or tri valent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CDS polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831572P | 2019-04-09 | 2019-04-09 | |
| EP19306261 | 2019-10-02 | ||
| PCT/US2020/027320 WO2020210392A1 (en) | 2019-04-09 | 2020-04-08 | Trispecific binding proteins, methods, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY208876A true MY208876A (en) | 2025-06-05 |
Family
ID=72751423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021005932A MY208876A (en) | 2019-04-09 | 2020-04-08 | Trispecific binding proteins, methods, and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3953388A1 (en) |
| JP (2) | JP7664175B2 (en) |
| KR (1) | KR20210149141A (en) |
| CN (1) | CN113950484B (en) |
| AU (1) | AU2020272839A1 (en) |
| BR (1) | BR112021019915A2 (en) |
| CA (1) | CA3136821A1 (en) |
| CO (1) | CO2021014918A2 (en) |
| IL (1) | IL286929A (en) |
| MX (1) | MX2021012386A (en) |
| MY (1) | MY208876A (en) |
| PH (1) | PH12021500041A1 (en) |
| SG (1) | SG11202111012QA (en) |
| TW (1) | TW202104261A (en) |
| WO (1) | WO2020210392A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020076853A1 (en) * | 2018-10-09 | 2020-04-16 | Sanofi | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
| TW202104274A (en) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | Trispecific and/or trivalent binding proteins for treatment of hiv infection |
| KR20250075711A (en) * | 2022-10-06 | 2025-05-28 | 비카라 테라퓨틱스 인크. | Multispecific proteins and related methods |
| WO2025027003A1 (en) | 2023-07-31 | 2025-02-06 | Sanofi | Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| JOP20210044A1 (en) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-CD38 . antibody |
| TWI803876B (en) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
| CN106687584B (en) * | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | Soluble antibody complexes for T cell or NK cell activation and expansion |
| MX381724B (en) * | 2014-11-20 | 2025-03-13 | Hoffmann La Roche | COMMON LIGHT CHAINS AND METHODS OF USE. |
| MA40972B1 (en) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecific antigen binding molecules activating t cells targeting folr1 and cd3 |
| TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| DK3310812T3 (en) * | 2015-06-17 | 2025-09-29 | Hoffmann La Roche | Anti-HER2 antibodies and methods of use |
| JP2018520139A (en) * | 2015-06-26 | 2018-07-26 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Methods for treating patients according to vaccination with eculizumab or eculizumab variants |
| HUE056608T2 (en) | 2015-10-25 | 2022-02-28 | Sanofi Sa | Trispecific and / or trivalent binding proteins for the prevention or treatment of HIV infection |
| WO2017180913A2 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| US12234479B2 (en) * | 2016-12-30 | 2025-02-25 | Cytocares (Shanghai) Inc. | Bifunctional molecule and use thereof |
| CN111788225B (en) * | 2017-10-10 | 2025-02-18 | 赛诺菲 | Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies |
| WO2020076853A1 (en) * | 2018-10-09 | 2020-04-16 | Sanofi | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
-
2020
- 2020-04-08 MY MYPI2021005932A patent/MY208876A/en unknown
- 2020-04-08 CA CA3136821A patent/CA3136821A1/en active Pending
- 2020-04-08 EP EP20722422.1A patent/EP3953388A1/en active Pending
- 2020-04-08 TW TW109111809A patent/TW202104261A/en unknown
- 2020-04-08 PH PH1/2021/500041A patent/PH12021500041A1/en unknown
- 2020-04-08 CN CN202080041550.1A patent/CN113950484B/en active Active
- 2020-04-08 SG SG11202111012QA patent/SG11202111012QA/en unknown
- 2020-04-08 KR KR1020217036094A patent/KR20210149141A/en active Pending
- 2020-04-08 JP JP2021559759A patent/JP7664175B2/en active Active
- 2020-04-08 MX MX2021012386A patent/MX2021012386A/en unknown
- 2020-04-08 AU AU2020272839A patent/AU2020272839A1/en active Pending
- 2020-04-08 BR BR112021019915A patent/BR112021019915A2/en unknown
- 2020-04-08 WO PCT/US2020/027320 patent/WO2020210392A1/en not_active Ceased
-
2021
- 2021-10-03 IL IL286929A patent/IL286929A/en unknown
- 2021-11-04 CO CONC2021/0014918A patent/CO2021014918A2/en unknown
-
2025
- 2025-01-20 JP JP2025007564A patent/JP2025063225A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113950484A (en) | 2022-01-18 |
| MX2021012386A (en) | 2022-01-18 |
| AU2020272839A1 (en) | 2021-12-02 |
| SG11202111012QA (en) | 2021-11-29 |
| CA3136821A1 (en) | 2020-10-15 |
| CN113950484B (en) | 2025-07-29 |
| WO2020210392A1 (en) | 2020-10-15 |
| BR112021019915A2 (en) | 2021-12-07 |
| IL286929A (en) | 2021-10-31 |
| PH12021500041A1 (en) | 2022-06-06 |
| JP2022527994A (en) | 2022-06-07 |
| KR20210149141A (en) | 2021-12-08 |
| JP7664175B2 (en) | 2025-04-17 |
| EP3953388A1 (en) | 2022-02-16 |
| TW202104261A (en) | 2021-02-01 |
| JP2025063225A (en) | 2025-04-15 |
| CO2021014918A2 (en) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502182A1 (en) | Trispecific and/or trivalent binding proteins | |
| PH12021500041A1 (en) | Trispecific binding proteins, methods, and uses thereof | |
| WO2017074878A8 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| AU2018277838C1 (en) | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof | |
| MX2024008521A (en) | Improved serum albumin binders. | |
| HRP20210041T1 (en) | COVALENTLY BONDED DIATIELS HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND PROCEDURES FOR THEIR USE | |
| EA202090718A1 (en) | PROTEINS BINDING NKG2D, CD16 AND LECTIN-LIKE C-TYPE MOLECULE-1 (CLL-1) | |
| EP4442707A3 (en) | Improved serum albumin binders | |
| PH12020500137A1 (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| WO2016130898A3 (en) | Antibody therapeutics that bind ctla4 | |
| WO2017053469A3 (en) | Cd3 binding polypeptides | |
| MX2021005048A (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof. | |
| MX2014005546A (en) | Albumin binding antibodies and binding fragments thereof. | |
| MX2018013342A (en) | The contorsbody - a single chain target binder. | |
| PH12022551231A1 (en) | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l | |
| MX2023004804A (en) | Trispecific and/or trivalent binding proteins. | |
| PH12021552148A1 (en) | Cd3 binding molecules | |
| MX2024002182A (en) | Tgf-beta-rii binding proteins. | |
| WO2021058711A3 (en) | Antigen binding proteins | |
| TN2018000345A1 (en) | Trispecific and/or trivalent binding proteins | |
| PH12021500042A1 (en) | Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection | |
| TN2018000137A1 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| EA202191078A2 (en) | TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | |
| NZ748144B2 (en) | Trispecific and/or trivalent binding proteins | |
| ATE492564T1 (en) | EPHB4-BINDING ANTIBODIES FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH |